Leukemia cutis (LC) can arise in the setting of hairy cell leukemia (HCL), a B-cell indolent lymphoid leukemia. This page outlines the clinical scenario and the general treatment approach when HCL underlies cutaneous leukemic infiltration.
Hairy cell leukemia is a subtype of B-cell indolent lymphoid leukemia. When leukemia cutis develops in this context, it represents cutaneous infiltration by malignant HCL cells, requiring systemic management directed at the underlying leukemia.
The primary clinical objective is disappearance of cutaneous infiltrates with complete resolution of the skin lesions.
One subtype of B-cell indolent lymphoid leukemia is hairy cell leukemia or HCL.
In HCL patients, LC responds well to purine analog treatment for leukemia and can be successfully treated with cladribine or pentostatin.
Treatment with cladribine also typically resulted in the disappearance of cutaneous infiltrates, with the complete resolution of the skin lesions.
DOI: 10.3390/cancers15225393
View source ↗